Hikma Pharmaceuticals has reached an agreement with Takeda Pharmaceutical Company to expand their licensing and distribution agreement to add new products to its existing portfolio in the Middle East and North Africa (MENA).

Under the deal, Hikma will have the right to register, manufacture, commercialise, distribute and sell four of Takeda's leading primary care products in 17 markets across the MENA region.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Hikma Pharmaceuticals MENA and Emerging Markets vice-chairman and CEO Mazen Darwazah said: “Our large sales and marketing teams, with particular expertise in promoting cardiovascular and diabetes treatments, are well positioned to drive patient access for Takeda’s products.

“We are pleased to be building on our partnership with Takeda to bring important medicines to the MENA region. By working with global partners we are strengthening our product portfolio in growing therapeutic areas and reinforcing our commitment to improving patient access to quality medicines.”

"We are pleased to be building on our partnership with Takeda to bring important medicines to the MENA region."

Effective immediately for all markets, the new agreement will enable Hikma to have exclusive rights to manufacture and commercialise three of Takeda's primary care product families in the MENA markets.

See Also:

The three-care product families include Alogliptin, including Alogliptin / Metformin, Alogliptin / Pioglitazone (anti-diabetic), Azilsartan, including Azilsartan / Chlorothalidone (anti-hypertensive) and Lornoxicam in its rapid form (anti-inflammatory / pain).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

However, the deal does not include the Egyptian market for Alogloptin.

In addition, Hikma has the exclusive rights to produce and commercialise Takeda's Dexlansoprozole in its MENA markets, excluding Saudi Arabia, the United Arab Emirates (UAE) and Egypt.

The company’s existing licence agreement with Takeda for Lornoxicam tablets (anti-inflammatory / pain) has been extended beyond Saudi Arabia and Jordan to cover its other MENA markets.